Gallstone disease in non-alcoholic fatty liver: Prevalence and associated factors

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 8, 2005, Pages 1176-1184

  Loria, Paola ^a,c   Lonardo, Amedeo ^b   Lombardini, Silvia ^a   Carulli, Lucia ^a   Verrone, Annamaria ^a   Ganazzi, Dorval ^a   Rudilosso, Antonia ^a   D'Amico, Roberto ^a   Bertolotti, Marco ^a   Carulli, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Modena City Hospital   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Apo B; Atherosclerosis; Cholecystectomy; Cholecystolitiasis; Insulin resistance; Metabolic syndrome; Non alcoholic fatty liver disease; Uric acid

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; URIC ACID;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; CHEMICAL ANALYSIS; CHOLECYSTECTOMY; CHOLELITHIASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FATTY LIVER; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK;

EID: 20444384546     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03924.x     Document Type: Article

References (57)

1. Browning JD, Horton JD. Gallstone disease and its complications. Semin. Gastrointest. Dis. 2003; 14: 165-77.
2. Attili AF, Carulli N, Roda E et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (MICOL). Am. J. Epidemiol. 1995; 141: 158-65.
3. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
4. Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000; 132: 112-17.
5. Diehl AK. Cholelithiasis and the insulin resistance syndrome. Hepatology 2000; 31: 528-30.
6. [No authors listed]. The epidemiology of gallstone disease in Rome, Italy. Part II. Factors associated with the disease. The Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO). Hepatology 1988; 8: 907-13.
7. Attili AF, Capocaccia R, Carulli N et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology 1997; 26: 809-18.
8. Misciagna G, Centonze S, Leoci C et al. Diet, physical activity, and gallstones: a population-based, case-control study in southern Italy. Am. J. Clin. Nutr. 1999; 69: 120-6.
9. Lonardo A, Bellini M, Tondelli E et al. Nonalcoholic steatohepatitis and the 'bright liver syndrome': should a recently expanded clinical entity be further expanded? Am. J. Gastroenterol. 1995; 90: 2072-4.
10. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
11. Lonardo A, Loria P, Carulli N. Insulin resistance in non-alcoholic fatty liver disease. In: Leuschner U, James O, Dancygier H, eds. Steatohepatitis (NASH and ASH). Dordrecht: Kluwer Academic Publishers, 2001; 104-13.
12. Loria P, Lonardo A, Lombardini S et al. Epidemiologia e storia naturale delle epatopatia steatosica nonalcolica. Ann. Ital. Med. Int. 2003; 18: 15S-31S.
13. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J. Gastroenterol. Hepatol. 2000; 15: 775-82.
14. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31: 299-303.
15. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-25.
16. Heaton KW. Review article: epidemiology of gall-bladder disease: role of intestinal transit. Aliment. Pharmacol. Ther. 2000; 14 (Suppl. 2): 9-13.
17. Ludwig J, Viggiano TR, McGill DB, Ott B. Non-alcoholic steatohepatitis. Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-8.
18. Nomura H, Kashiwagi S, Hayashi J et al. Prevalence of gallstone disease in a general population of Okinawa, Japan. Am. J. Epidemiol. 1988; 128: 598-605.
19. Lu SN, Chang WY, Wang LY et al. Risk factors for gallstones among Chinese in Taiwan. A community sonographic survey. J. Clin. Gastroenterol. 1990; 12: 542-6.
20. Lonardo A, Loria P, Leonardi F et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of nonalcoholic fatty liver disease. A case-control study. Dig. Liver Dis. 2002; 34: 204-11.
21. Loria P, Lonardo A, Leonardi F et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig. Dis. Sci. 2003; 48: 2173-81.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
23. Yokoyama H, Emoto M, Fujiwara S et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. J. Clin. Endocrinol. Metab. 2004; 89: 1481-4.
24. Valenti L, Fracanzani AL, Dongiovanni P et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
25. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart study. Diabetes Care 1997; 20: 1087-92.
26. The Expert Committee on the Diagnosis and Clasification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl. 1): S1-147.
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
28. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin. Liver Dis. 2001; 21: 3-16.
29. Barbara L, Sama C, Morselli Labate AM et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology 1987; 7: 913-17.
30. Loria P, Dilengite MA, Bozzoli M et al. Prevalence rates of gallstone disease in Italy. The Chianciano population study. Eur. J. Epidemiol. 1994; 10: 143-50.
31. Dowling RH. Pathogenesis of gallstones. Aliment. Pharmacol. Ther. 2000; 14 (Suppl. 2): 39-47.
32. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-19.
33. Mathus-Vliegen EM, Van lerland-Van Leeuwen ML, Terpstra A. Determinants of gallbladder kinetics in obesity. Dig. Dis. Sci. 2004; 49: 9-16.
34. Pazzi P, Scagliarini R, Gamberini S, Pezzoli A. Gall-bladder motor function in diabetes mellitus. Aliment. Pharmacol. Ther. 2000; 14 (Suppl. 2): 62-5.
35. Ahlberg J, Angelin B, Einarsson K, Hellstrom K, Leijd B. Biliary lipid composition in normo- and hyperlipoproteinemia. Gastroenterology 1980; 79: 90-4.
36. Jonkers IJ, Smelt AH, Ledeboer M et al. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 2003; 52: 109-15.
37. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
38. Musso G, Gambino R, De Michieli F et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-16.
39. Veysey MJ, Thomas LA, Mallet AI et al. Colonic transit influences deoxycholic acid kinetics. Gastroenterology 2001; 121: 812-22.
40. Carulli N, Loria P, Bertolotti M et al. Effects of acute changes of bile acid pool composition on biliary lipid secretion. J. Clin. Invest. 1984; 74: 614-24.
41. Maitra A, La Voie HA, Day RN, Garmey JC, Veldhuis JD. Regulation of porcine granulosa cell 3-hydroxy-3-methylglutaryl coenzyme A reductase by insulin and insulin-like growth factor I: synergism with follicle-stimulating hormone or protein kinase A agonist. Endocrinology 1995; 136: 5111-17.
42. Twisk J, Hoekman MF, Lehmann EM, Meijer P, Mager WH, Princen HM. Insulin suppresses bile acid synthesis in cultured rat hepatocytes by down-regulation of cholesterol 7 alpha-hydroxylase and sterol 27-hydroxylase gene transcription. Hepatology 1995; 21: 501-10.
43. Simonen PP, Gylling H, Miettinen TA. Body weight modulates cholesterol metabolism in non-insulin dependent type 2 diabetics. Obes. Res. 2002; 10: 328-35.
44. Horton JD, Shimomura I. Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis. Curr. Opin. Lipidol. 1999; 10: 143-50.
45. Xu G, Muller O, Stange EF, Fuchs M. Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice. Biochim. Biophys. Acta 2004; 1688: 274-9.
46. Dubrac S, Parquet M, Blouquit Y et al. Insulin injections enhance cholesterol gallstone incidence by changing the biliary cholesterol saturation index and apo A-I concentration in hamsters fed a lithogenic diet. J. Hepatol. 2001; 35: 550-7.
47. Grundy SM. Cholesterol gallstones: a fellow traveler with metabolic syndrome? Am. J. Clin. Nutr. 2004; 80: 1-2.
48. Fornaciari G. Renaissance mummies in Italy. Med. Secoli. 1999; 11: 85-105.
49. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr. 1956; 4: 20-34.
50. Huth K, Burkard M, Goebel T. Dyslipoproteinemia and diabetes mellitus in a metabolic syndrome. Fortschr. Med. 1992; 110: 200-4.
51. Kane GP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 7th edn, Vol. 2. NY: McGraw-Hill, 1995; 1853-85.
52. Lonardo A, Loria P. Apolipoprotein synthesis in non-alcoholic steatohepatitis. Hepatology 2002; 36: 514-15 (Letter).
53. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.
54. Tang WH. Serum and bile lipid levels in patients with and without gallstones. J. Gastroenterol. 1996; 31: 823-7.
55. Han T, Jiang Z, Suo G, Zhang S. Apolipoprotein B-100 gene Xba I polymorphism and cholesterol gallstone disease. Clin. Genet. 2000; 57: 304-8.
56. Moran S, Duque-Lopez MX, Salmeron-Castro J, Rodriguez-Leal G, Martinez-Salgado H, Uribe M. Association between serum concentration of apolipoproteins A-I and B with gallbladder disease. Arch. Med. Res. 2003; 34: 194-9.
57. Bugianesi E, Marchesini G. Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. Hepatology 2004; 39: 1749.